Tech Company Financing Transactions
Feldan Therapeutics Funding Round
Amgen Ventures, FSIT2 and GC Cell joined a $16.5 million Series B funding round for Feldan Therapeutics. The round was announced by the company on 6/13/2023.
Transaction Overview
Company Name
Announced On
6/13/2023
Transaction Type
Venture Equity
Amount
$16,500,000
Round
Series B
Proceeds Purpose
The company intends to use the funds to conduct clinical phases I/II for Feldan's FLD-103, an intralesional treatment against basal cell carcinoma (BCC), and to advance its pulmonary program to the preclinical stage.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4975 Rideau St. 100
Quebec QC, G2E 5H5
Canada
Quebec QC, G2E 5H5
Canada
Phone
Website
Email Address
Overview
We produce high-quality cytokines and proteins for your scientific needs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Francois-Thomas Michaud
VP - Bus. Development
Vincent Ménard
VP - Bus. Development
Nancy Messier
VP - Marketing
Meriem Benchabane
VP - Operations
Pierre-Alain Moisset
VP - R & D
David Guay
Browse more venture capital transactions:
Prev: 6/13/2023: Pollen venture capital transaction
Next: 6/13/2023: Synthesia venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC transactions on this site are derived from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs